See the DrugPatentWatch profile for nivolumab

Nivolumab is a type of immunotherapy drug designed to boost the body's natural defenses to fight cancer. It is a programmed death receptor-1 (PD-1) blocking antibody that works by increasing the ability of the body's immune system to help detect and fight tumor cells [1].

The duration of nivolumab's immune-boosting effects can vary significantly from person to person, depending on several factors such as the type of cancer, the stage of the disease, the patient's overall health, and the specific treatment regimen [2].

In clinical trials, some patients have experienced lasting responses to nivolumab for several years [3]. However, it is important to note that not all patients will respond to nivolumab, and some may experience only temporary benefits [4].

According to DrugPatentWatch.com, nivolumab is currently approved for the treatment of several types of cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma [5].

In summary, the duration of nivolumab's immune-boosting effects can vary significantly from person to person, and it is important for patients to discuss their individual treatment plans and expectations with their healthcare providers.

Sources:
[1] National Cancer Institute. "Nivolumab." <https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab>.
[2] American Society of Clinical Oncology. "Nivolumab." <https://www.cancer.net/drugs/nivolumab>.
[3] National Comprehensive Cancer Network. "NCCN Guidelines for Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors." <https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf>.
[4] American Cancer Society. "Immunotherapy for Cancer." <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immunotherapy-how-it-works.html>.
[5] DrugPatentWatch.com. "Nivolumab (Opdivo)." <https://www.drugpatentwatch.com/drugs/nivolumab>.